These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 16703381)

  • 1. [Antibiotic therapy: progress and development of resistance].
    Adam D
    Internist (Berl); 2006 Jul; 47(7):758-63. PubMed ID: 16703381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
    Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New therapeutic options for the treatment of multiresistant bacteria in the ICU].
    Barcenilla Gaite F; Jover Saenz A; Vallverdú Vidal M; Castellana Perello D
    Rev Esp Quimioter; 2008; 21 Spec No 1():9-13. PubMed ID: 18752075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in antibacterial therapy against emerging bacterial pathogens.
    Pournaras S; Iosifidis E; Roilides E
    Semin Hematol; 2009 Jul; 46(3):198-211. PubMed ID: 19549574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for multidrug-resistant bacteria.
    Giamarellou H
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):601-18. PubMed ID: 17009940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients.
    Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD
    J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers.
    Mauldin PD; Salgado CD; Durkalski VL; Bosso JA
    Ann Pharmacother; 2008 Mar; 42(3):317-26. PubMed ID: 18285560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial resistance in gram-positive bacteria.
    Rice LB
    Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appropriate antibiotic use and why it is important: the challenges of bacterial resistance.
    Lieberman JM
    Pediatr Infect Dis J; 2003 Dec; 22(12):1143-51. PubMed ID: 14688589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New agents in development for the treatment of bacterial infections.
    Abbanat D; Morrow B; Bush K
    Curr Opin Pharmacol; 2008 Oct; 8(5):582-92. PubMed ID: 18761107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus].
    Mensa J; Barberán J; Llinares P; Picazo J; Bouza E; Alvarez-Lerma F; Borges M; Serrano R; León C; Guirao X; Arias J; Carreras E; Sanz M; García-Rodríguez J; ; ; ; ; ;
    Rev Esp Quimioter; 2008 Dec; 21(4):234-58. PubMed ID: 19031124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT; Liao CH; Teng LJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Has the era of untreatable infections arrived?
    Livermore DM
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i29-36. PubMed ID: 19675016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
    French GL
    J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial resistance in gram-positive bacteria.
    Rice LB
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S11-9; discussion S64-73. PubMed ID: 16813977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What's new on the antimicrobial horizon?
    Song JH
    Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S207-13. PubMed ID: 19134521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.